NORINYL 1+35 28-DAY
LOE ApproachingNDAORAL-28TABLET
Approved
Dec 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NORINYL 1+35 is an oral contraceptive containing norethindrone 1 mg and ethinyl estradiol 35 mcg in a 28-day cycle tablet formulation. It prevents pregnancy through hormonal suppression of ovulation and alterations to cervical mucus and endometrium. This is a legacy small-molecule oral contraceptive product.
LOE Approaching
Product approaching end-of-life with moderate competitive pressure (30/100); teams are typically maintenance-focused with limited growth investment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on NORINYL 1+35 offers limited career growth given its LOE-approaching lifecycle and established generic competition. Roles are primarily focused on defending market share, managing brand relationships with providers, and ensuring compliance—valuable for building operational expertise but not ideal for advancement into innovation-focused positions.
Brand Manager (Legacy)
Worked on NORINYL 1+35 28-DAY at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.